GlassScriptPhysician profile
Joseph Ryan Shows
NPI 1972795250
$2,969.96
in general payments reported to CMS, 2019-2025
33 companies · $641 in 2025
The $641 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $93.99 · 2021: $14.96 · 2022: $840 · 2023: $712 · 2024: $525 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $472.34 | 2019-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $438.25 | 2021-2025 | |
| Pfizer INC. | $381.06 | 2019-2025 | |
| Abbvie INC. | $180.55 | 2024-2025 | |
| Medtronic, INC. | $150.31 | 2024 | Osteocool Rf Ablation System |
| Pharmacyclics LLC, An Abbvie Company | $143.10 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $127.61 | 2022-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $97.46 | 2019-2023 | Keytruda |
| Daiichi Sankyo INC. | $90.22 | 2023-2025 | Enhertu, Injectafer |
| Amgen INC. | $88.75 | 2020-2022 | |
| Array Biopharma INC | $82.79 | 2025 | Lorbrena, Mektovi, Braftovi |
| Veracyte, INC. | $71.98 | 2023 | |
| Blueprint Medicines Corporation | $69.01 | 2022-2023 | Ayvakit |
| Incyte Corporation | $64.48 | 2022-2023 | Monjuvi |
| Astellas Pharma US INC | $52.95 | 2023-2025 | Xtandi, Padcev |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.36 | 2022-2023 | Imfinzi |
| Janssen Biotech, INC. | $48.42 | 2022 | |
| G1 Therapeutics, INC. | $47.33 | 2022-2023 | Cosela |
| Progenics Pharmaceuticals, INC. | $45.86 | 2023 | Pylarify |
| Cti Biopharma Corp. | $36.13 | 2022 | |
| Dendreon Pharmaceuticals LLC | $35.21 | 2025 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $31.86 | 2022-2023 | Opdivo |
| Menarini Silicon Biosystems, INC. | $22.18 | 2025 | |
| Genzyme Corporation | $18.87 | 2023 | |
| Tempus Ai, INC | $18.69 | 2024 | |
| Seagen INC. | $17.19 | 2022 | |
| Beigene USA, INC. | $17.15 | 2023 | Brukinsa |
| Recordati_rare_diseases_inc. | $16.32 | 2025 | Sylvant |
| Agios Pharmaceuticals, INC. | $15.61 | 2025 | Pyrukynd |
| Eisai INC. | $13.35 | 2022 | |
| Genentech USA, INC. | $12.13 | 2022 | |
| Rigel Pharmaceuticals, INC. | $10.44 | 2023 | Rezlidhia, Tavalisse |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Shows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.